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Statins, widely used to lower cholesterol levels, cause myopathy in some patients. Mangravite et al. (2013)
show that a single nucleotide polymorphism decreasing expression of glycine amidinotransferase (GATM),
the enzyme regulating creatine biosynthesis, is associated with reduced statin myopathy. Whether reduced
creatine production protects against statin myopathy remains to be determined.Hydroxy-methyl-glutaryl Co-A (HMGCoA)
reductase inhibitors or ‘‘statins’’ inhibit
mevalonate production, ultimately re-
ducing low-density lipoprotein (LDL)
cholesterol concentrations and cardiovas-
cular morbidity and mortality. Statins are
extremely well tolerated but can produce
skeletal muscle adverse effects in some
patients, ranging from myalgia (muscle
pain), cramps, weakness, and stiffness to
markedly elevated creatine kinase (CK)
levels, indicating skeletal muscle damage
and rhabdomyolysis (muscle breakdown).
It is assumed that all of thesemuscle com-
plaints are produced by the same mecha-
nism, but this is not certain and at least
one muscle side effect, an autoimmune
myositis (muscle inflammation), is associ-
ated with antibodies against HMG CoA
reductase (Mohassel and Mammen,
2013). Statin-induced rhabdomyolysis
and autoimmune myositis are extremely
rare, but the STOMP (Effect of Statins on
Muscle Performance) study (Parker et al.,
2013) reported that treatment with high-
dose atorvastatin, one of the most
commonly prescribed statins, doubled
the incidence of myalgia compared with
placebo from 4.6% to 9.4%, suggesting
that the overall incidence of statin myalgia
is approximately 5%. Statins are among
the most widely prescribed medicines
worldwide, making prediction of who can
and cannot tolerate these drugs an impor-
tant issue.Numerouspossible genetic var-
iants affecting statin myopathy have been
identified (Ghatak et al., 2010). Mangravite
and colleagues (Mangravite et al., 2013)
now identify a variant in the gene for
glycine amidinotransferase (GATM), the
rate-limiting enzyme required for creatine
biosynthesis, as a possible genetic
contributor to statin myopathy.The findings of Mangravite et al. add
to the growing list of genetic variants
associated with statin-related muscle
complaints. These include the gene for
the organic anion transporter, SLCO1B1.
The SLCO1B1 *5 variant (rs4149056) is
associatedwith reduced hepatic statin up-
take and increased myalgia (Voora et al.,
2009) and rhabdomyolysis (Link et al.,
2008), suggesting that reduced hepatic
uptake increases the amount of statin
that survives hepatic passage and can
enter skeletal muscle. Variants in genes in
the cytochrome P enzyme system (CYP),
which catabolize statins, may also affect
the frequency of statinmyopathy,although
these variants, inCYP3A4/5,CYP2D6, and
CYP2C9, appear most important when
statins are combined with other drugs
metabolized by the same CYP enzyme
(Ghatak et al., 2010). Variants in the
COQ2 gene, a component of the coen-
zyme Q10 (CoQ10) production pathway,
have also been proposed to affect statin
myalgia. CoQ10 is a mitochondrial elec-
tron transport protein that is alsoproduced
by themevalonate pathway.Reductions in
CoQ10 production could adversely affect
cellular energy production. These are
only three of multiple possible genetic var-
iants affecting statin myopathy (Ghatak
et al., 2010).
Mangravite and colleagues (Mangravite
et al., 2013) are the first to identify creatine
biosynthesis as another possible contrib-
utor to statin myopathy. Creatine, or
methylguanidine acetic acid, is synthe-
sized predominantly in the liver and kid-
neys by a two-reaction pathway utilizing
glycine, arginine, and methionine. Crea-
tine is then transported to skeletal muscle
where it combines with inorganic phos-
phate to form creatine phosphate (CP).Cell Metabolism 18,CP is rapidly split by CK to produce crea-
tine and inorganic phosphate. The latter
combines with ADP to form ATP. CP
thus serves as an important cellular
energy source for rapid resynthesis of
ATP to meet the energy demands of
intense activities.
Mangravite et al. (2013) useda genome-
wide expression quantitative trait loci
(eQTL) analysis in lymphoblastoid cell
lines (LCLs) from480middle-aged healthy
volunteers from a simvastatin treatment
trial. LCLs, which are a common model
system to screen for genetic variants,
were exposed to simvastatin or control
buffer for 24 hr. Six eQTL were identified
that interact with simvastatin exposure.
These included a single nucleotide
polymorphism rs9806699 in GATM. Sim-
vastatin exposure produced a 2-fold
greater reduction in GATM expression in
cells from rs9806699 carriers than in
cells from noncarriers. Reduced GATM
expression should reduce creatine syn-
thesis. Furthermore, the relationship be-
tween the GATM differential eQTL locus
expression with simvastatin exposure
and statin-induced myopathy was exam-
ined in two separate population-based
cohorts comprising 172 cases of myop-
athy (Link et al., 2008; Mareedu et al.,
2009). Calculation of an odds ratio to
quantify the association between pres-
ence of the rs9806699 variant and statin
myopathy resulted in an overall odds ratio
of 0.60 (95% confidence interval = 0.45–
0.81) with meta-analysis of these two co-
horts, suggesting that reduced GATM
expression, and probable reduced crea-
tine synthesis, is associated with a
reduced incidence of statin-induced
myopathy. Collectively, these data are
the first to identify a genetic variantDecember 3, 2013 ª2013 Elsevier Inc. 773
Figure 1. Proposed Mechanism by which Reduced GATM Activity
Reduces Statin Myopathy Risk
Simvastatin reduced GATM transcriptional expression, and this effect was
associated with a reduced incidence of statin myopathy (Mangravite et al.,
2013). Reduced intramuscular Cr may protect against statin-induced myop-
athy. GATM, glycine amidinotransferase; CP, creatine phosphate; Cr, creatine.
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and highlight reduced intra-
muscular creatine as a poten-
tial protector against statin-
induced muscle problems.
The authors propose that
simvastatin reduced GATM
expression in rs9806699 car-
riers, reducing creatine avail-
ability and CP storage. They
speculate that reduced CP
storage modifies skeletal
muscle cellular energy path-
ways leading to reduced sus-
ceptibility to statin myopathy
(Figure 1).
This is a unique hypoth-
esis, but questions remain.
No prior studies, including
several genome-wide associ-
ation studies (GWAS) (Link
et al., 2008; Ruan˜o et al.,
2011), have identified the
GATM gene as a contributorto statin myopathy. In the study by Man-
gravite et al. (2013), statin myopathy in
their cohortswasdefinedbyCKelevations
three to ten times the upper-normal limits
(Link et al., 2008; Mareedu et al., 2009).
But perhaps the rs9806699 variant re-
duces both myocyte creatine and CK
levels so that any skeletal muscle injury
produces less CK elevation and fewer
diagnoses of statin myopathy. Arguing
against this possibility is the observation
that plasma CK levels measured before
and after statin treatmentwere not associ-
ated with the GATM variant in subjects
without myopathy (Mangravite et al.,
2013), but this does not address the possi-
bility that intramuscular CK levels are
related to the GATM genotype. Also, in774 Cell Metabolism 18, December 3, 2013 ªcontrast to the authors’ hypothesis (Man-
gravite et al., 2013), GATM deficiency
was associated with a myopathy in two
siblings that improved with oral creatine
treatment (Edvardson et al., 2010), sug-
gesting that depleting intramuscular
creatine does not protect against, but
causes, myopathy. Over-the-counter cre-
atine supplementation actually appeared
to reduce statin-associated muscle com-
plaints in ten patients with statin myalgia,
but these data (Shewmon and Craig,
2010) warrant investigation in a much
larger cohort.
In summary, these data (Mangravite
et al., 2013) identifying a statin-responsive
genetic variant in GATM expression
associated with reduced susceptibility to2013 Elsevier Inc.statin-induced myopathy are
intriguing but require addi-
tional study to determine their
significance.
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